The prevalence and predictors of cardiovascular diseases in Kherameh cohort study: a population-based study on 10,663 people in southern Iran.
Cardiovascular disease
Kherameh cohort
Predictors
Prevalence
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
28 05 2022
28 05 2022
Historique:
received:
23
02
2022
accepted:
19
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
The prevalence of cardiovascular disease (CVD) is rapidly increasing in the world. The present study aimed to assess the prevalence and Predictors factors of CVD based on the data of Kherameh cohort study. The present cross-sectional, analytical study was done based on the data of Kherameh cohort study, as a branch of the Prospective Epidemiological Studies in Iran (PERSIAN). The participants consisted of 10,663 people aged 40-70 years. CVD was defined as suffering from ischemic heart diseases including heart failure, angina, and myocardial infarction. Logistic regression was used to model and predict the factors related to CVD. Additionally, the age-standardized prevalence rate (ASPR) of CVD was determined using the standard Asian population. The ASPR of CVD was 10.39% in males (95% CI 10.2-10.6%) and 10.21% in females (95% CI 9.9-10.4%). The prevalence of CVD was higher among the individuals with high blood pressure (58.3%, p < 0.001) as well as among those who smoked (28.3%, p = 0.018), used opium (18.2%, p = 0.039), had high triglyceride levels (31.6%, p = 0.011), were overweight and obese (66.2%, p < 0.001), were unmarried (83.9%, p < 0.001), were illiterate (64.2%, p < 0.001), were unemployed (60.9%, p < 0.001), and suffered from diabetes mellitus (28.1%, p < 0.001). The results of multivariable logistic regression analysis showed that the odds of having CVD was 2.25 times higher among the individuals aged 50-60 years compared to those aged 40-50 years, 1.66 folds higher in opium users than in non-opium users, 1.37 times higher in smokers compared to non-smokers, 2.03 folds higher in regular users of sleeping pills than in non-consumers, and 4.02 times higher in hypertensive individuals than in normotensive ones. The prevalence of CVD was found to be relatively higher in Kherameh (southern Iran) compared to other places. Moreover, old age, obesity, taking sleeping pills, hypertension, drug use, and chronic obstructive pulmonary disease had the highest odds ratios of CVD.
Sections du résumé
BACKGROUND
The prevalence of cardiovascular disease (CVD) is rapidly increasing in the world. The present study aimed to assess the prevalence and Predictors factors of CVD based on the data of Kherameh cohort study.
METHODS
The present cross-sectional, analytical study was done based on the data of Kherameh cohort study, as a branch of the Prospective Epidemiological Studies in Iran (PERSIAN). The participants consisted of 10,663 people aged 40-70 years. CVD was defined as suffering from ischemic heart diseases including heart failure, angina, and myocardial infarction. Logistic regression was used to model and predict the factors related to CVD. Additionally, the age-standardized prevalence rate (ASPR) of CVD was determined using the standard Asian population.
RESULTS
The ASPR of CVD was 10.39% in males (95% CI 10.2-10.6%) and 10.21% in females (95% CI 9.9-10.4%). The prevalence of CVD was higher among the individuals with high blood pressure (58.3%, p < 0.001) as well as among those who smoked (28.3%, p = 0.018), used opium (18.2%, p = 0.039), had high triglyceride levels (31.6%, p = 0.011), were overweight and obese (66.2%, p < 0.001), were unmarried (83.9%, p < 0.001), were illiterate (64.2%, p < 0.001), were unemployed (60.9%, p < 0.001), and suffered from diabetes mellitus (28.1%, p < 0.001). The results of multivariable logistic regression analysis showed that the odds of having CVD was 2.25 times higher among the individuals aged 50-60 years compared to those aged 40-50 years, 1.66 folds higher in opium users than in non-opium users, 1.37 times higher in smokers compared to non-smokers, 2.03 folds higher in regular users of sleeping pills than in non-consumers, and 4.02 times higher in hypertensive individuals than in normotensive ones.
CONCLUSION
The prevalence of CVD was found to be relatively higher in Kherameh (southern Iran) compared to other places. Moreover, old age, obesity, taking sleeping pills, hypertension, drug use, and chronic obstructive pulmonary disease had the highest odds ratios of CVD.
Identifiants
pubmed: 35643460
doi: 10.1186/s12872-022-02683-w
pii: 10.1186/s12872-022-02683-w
pmc: PMC9148515
doi:
Substances chimiques
Sleep Aids, Pharmaceutical
0
Opium
8008-60-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244Informations de copyright
© 2022. The Author(s).
Références
Am J Respir Crit Care Med. 2016 Feb 1;193(3):251-8
pubmed: 26414484
Glob Heart. 2018 Jun;13(2):73-82.e1
pubmed: 29434010
Front Public Health. 2020 Jan 21;7:411
pubmed: 32039127
Vasc Health Risk Manag. 2016 Mar 17;12:75-84
pubmed: 27051290
J Am Heart Assoc. 2016 Jul 22;5(7):
pubmed: 27451464
Int J Hypertens. 2015;2015:897070
pubmed: 26783454
Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:43-73
pubmed: 16092717
J Health Care Poor Underserved. 2011;22(4 Suppl):61-72
pubmed: 22102306
Am J Respir Crit Care Med. 2016 Sep 1;194(5):568-76
pubmed: 27442601
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Lancet. 2010 Jan 16;375(9710):181-3
pubmed: 20109902
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
Atherosclerosis. 2015 Jul;241(1):211-8
pubmed: 25670232
Arch Gen Psychiatry. 1979 Jan;36(1):103-16
pubmed: 760693
J Hum Hypertens. 2021 Mar;35(3):257-264
pubmed: 32203076
Nat Rev Cardiol. 2009 Nov;6(11):712-22
pubmed: 19770848
BMC Cardiovasc Disord. 2021 Jan 2;21(1):2
pubmed: 33388044
Iran J Public Health. 2019 Oct;48(10):1937-1939
pubmed: 31850279
S Afr Med J. 2015 Jan 05;105(2):134-8
pubmed: 26242533
Clin Med (Lond). 2006 Nov-Dec;6(6):559-72
pubmed: 17228555
BMJ Open. 2018 Aug 20;8(8):e020282
pubmed: 30127048
Thorax. 2010 Nov;65(11):956-62
pubmed: 20871122
Diabetes Metab Syndr Obes. 2019 Oct 24;12:2221-2236
pubmed: 31695465
BMC Cardiovasc Disord. 2020 May 19;20(1):238
pubmed: 32429905
Circulation. 2008 Mar 25;117(12):1526-36
pubmed: 18347213
Acta Med Scand Suppl. 1982;660:69-83
pubmed: 6982602
JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
Bull World Health Organ. 2000;78(11):1296-305
pubmed: 11143189
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1319-1336
pubmed: 27589227
Ann Epidemiol. 2006 Jan;16(1):63-70
pubmed: 16039877
PLoS One. 2013 May 20;8(5):e63347
pubmed: 23700418
Ann Intern Med. 1976 Oct;85(4):447-52
pubmed: 970770
Am J Cardiol. 2004 May 15;93(10):1295-7
pubmed: 15135709
J Palliat Med. 2009 Jan;12(1):77-82
pubmed: 19284267
Am J Epidemiol. 2018 Apr 1;187(4):647-655
pubmed: 29145581
Arch Intern Med. 2003 Jan 27;163(2):205-9
pubmed: 12546611
Am J Kidney Dis. 2010 Mar;55(3):590-8
pubmed: 19962803
Clin Geriatr Med. 2009 Nov;25(4):563-77, vii
pubmed: 19944261
Circulation. 1998 Feb 17;97(6):596-601
pubmed: 9494031
Circ Res. 2012 Apr 13;110(8):1097-108
pubmed: 22499900
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16263-8
pubmed: 17923677
J Cardiovasc Risk. 1996 Apr;3(2):213-9
pubmed: 8836866
Arch Intern Med. 2007 Jun 11;167(11):1130-6
pubmed: 17563020
Adv Exp Med Biol. 2017;956:419-426
pubmed: 27815926
J Bioeth Inq. 2017 Jun;14(2):275-286
pubmed: 28470503
Sleep. 1983;6(2):102-7
pubmed: 6878979
Pharmacol Res. 2018 Mar;129:95-99
pubmed: 29127059
Lancet Respir Med. 2015 Aug;3(8):631-9
pubmed: 26208998
Subst Abuse Treat Prev Policy. 2020 Apr 17;15(1):30
pubmed: 32303254
Planta Med. 2011 Nov;77(17):1870-5
pubmed: 21800277
Caspian J Intern Med. 2013 Winter;4(1):585-9
pubmed: 24009941
J Am Coll Cardiol. 2004 May 19;43(10):1731-7
pubmed: 15145091
Prog Cardiovasc Dis. 2019 Jul - Aug;62(4):306-314
pubmed: 31301314
Am J Hypertens. 2013 Jan;26(1):83-94
pubmed: 23382331
BMJ Open. 2015 Sep 11;5(9):e007824
pubmed: 26362660
Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):329-55
pubmed: 12099666
Glob Health Action. 2014 Mar 27;7:23286
pubmed: 24679543
Am J Clin Nutr. 2012 Dec;96(6):1390-7
pubmed: 23076619
Nihon Rinsho. 2008 Sep;66(9):1657-63
pubmed: 18788391
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
BMJ. 2018 Jan 24;360:j5855
pubmed: 29367388
Curr Probl Cardiol. 2010 Feb;35(2):72-115
pubmed: 20109979
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Circulation. 2019 Feb 19;139(8):1025-1035
pubmed: 30779652
Am Heart J. 2004 Jul;148(1):7-15
pubmed: 15215786
J Am Coll Cardiol. 2009 May 26;53(21):1925-32
pubmed: 19460605
Eur Heart J. 2017 Dec 21;38(48):3567-3568
pubmed: 29140424
J Diabetes Res. 2018 Nov 4;2018:3407306
pubmed: 30525052
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Eur J Public Health. 2011 Feb;21(1):81-91
pubmed: 20237171
Curr Cardiol Rev. 2010 Feb;6(1):54-61
pubmed: 21286279
Clin Med Insights Cardiol. 2011;5:67-75
pubmed: 21836815
BMC Public Health. 2011 Jul 15;11:567
pubmed: 21756367